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ABSTRACT
Parrish, Austin R. M.S. Department of Neuroscience Cell Biology & Physiology,
Wright State University, 2019. Effect of hybrid/complex N-glycosylation on
cardiac voltage-gated ion channel expression

Dilated cardiomyopathy (DCM) is one the most common forms of heart failure,
with the majority of cases being idiopathic. Dr. Bennett’s laboratory previously
showed that deletion of the Mgat1 gene in cardiomyocytes only (Mgat1KO) is
sufficient to cause DCM leading to heart failure and early death. The Mgat1 gene
product, GlcNAcT1, is responsible for initiating the formation of hybrid/complex
N-glycosylation. These data suggest a link between abnormal glycosylation and
heart disease; however, there is a mystery of how the specific changes in
glycosylation contribute to heart disease etiology and progression. The proper
function and gating of voltage-gated Na+ channels (Nav) and voltage-gated
K+ channels (Kv) are vital to the initiation, shape, and conduction of the
cardiomyocyte action potential (AP); thus, abnormal channel activity contributes
to arrhythmias and other heart diseases. Other labs as well as our own, have
shown that modest reductions in channel glycosylation can alter gating of Nav
and Kv through electrostatic mechanisms with no change in channel expression
levels. Thus, here and in a recent publication by Ednie, Parrish, Sonner, and
Bennett entitled, “Reduced Hybrid/Complex N-glycosylation Disrupts Cardiac
Electrical Signaling and Calcium Handling in a Model of Dilated
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Cardiomyopathy“, we showed that cardiomyocyte-specific deletion of Mgat1 that
leads to reduced hybrid/complex protein N-glycosylation modulates Nav and Kv
activity through direct and indirect mechanisms. Here, we show that Mgat1KO
Nav expression was not different between Mgat1KO and control ventricular
myocytes; however, there was a reduction in Mgat1KO Nav molecular weight,
suggesting that Nav are direct targets of GlcNAcT1 similar to Cav a2d1. We found
that Kv4.2 and Kv1.5 expression levels are significantly lower in the older
Mgat1KO ventricular myocyte compared to controls, consistent with an indirect,
but disease-related decrease in Kv expression and, as a result, K+ current. Thus,
utilization of the Mgat1KO DCM model will allow one to continue uncovering
mechanistic glycosylation-dependent links between aberrant electrical signaling
and heart disease onset and progression.
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I.

INTRODUCTION

A. Electrical Signaling, Conduction, and Contraction
The human heart is a critical organ that provides for human life as well as
maintains homeostasis by transporting nutrients, oxygen, and hormones.
Without the pumping heart, life would end in a few short minutes. The heart is
part of the cardiovascular system that works synergistically with blood as well as
blood vessels. It is composed of four major chambers: the right atrium and right
ventricle, and left atrium and left ventricle that carry deoxygenated and
oxygenated blood respectively. Coronary arteries supply the heart with nutrients
that are located on the visceral pericardium. The heart is composed of four
layers: pericardium, epicardium, myocardium and endocardium. Specifically, at
the anatomical layer, the heart wall is composed of just three layers: epicardium,
which is the outermost protective layer to the heart, myocardium, which is the
muscular layer that contains the cardiomyocytes (cardiac tissue is solely located
within the myocardial layer of the heart), and endocardium, which is the inner
most layer is composed of simple squamous epithelium. This cardiac tissue is
understood as involuntary, meaning mammals are not able to control the
mechanical action that the heart provides. The anatomical pacemaker (sinoatrial
node) can be located in the right atrium, near where the superior vena cava
opens. The sinoatrial node (SA node) initiates the electrical signaling in the form
of action potentials (AP), which conduct through the conduction system and then
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results in exciting the myocardium. The myocardium subsequently contracts
which allows the heart to pump blood. The SA node sets up the heart rate,
which, in humans, normally ranges from 60 – 100 beats per minute and is the
source of sinus rhythms – allowing for the atria to fully contract before the
ventricles.
The cells located in the SA node have self-sustaining and rhythmic
changes in membrane potential. Specifically, they are found to have a slow
spontaneous
depolarization
during the period of
diastole (1,2). This
is due to the fact
that SA nodal cells
are modified
cardiomyocytes,
not actual
myocytes that are
Figure 1: Electrical physiology of the myocardium in a human heart,
with illustrated action potentials in the different conduction cells.
Figure was taken (with permission) from Nerbonne and Kass (30).

responsible for the
contraction of the

heart. The resting membrane potential for the SA node is approximately -60 mV
and slowly depolarizes to approximately -40 mV, where threshold is achieved
producing AP. However, the cardiomyocytes within the myocardium have a
resting membrane potential roughly -90 to -80 mV (2,3). The AP waveform of SA
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nodal cells versus cardiomyocytes are quite distinct as shown in figure 1.
Beginning with the SA nodal cells, the “funny current” (If) is conducted by a
hyperpolarization-activated Na+ current, the voltage allowing for a gradual
depolarization to threshold. Once the nodal cells reach threshold, voltage-gated
Ca2+ channels (Cav) open causing rapid depolarization. From here voltage-gated
K+ channels (Kv) repolarize the cell, returning it to its resting membrane potential.
The AP’s generated from the SA node conduct along anterointernal pathways
throughout atrial myocardium, via gap junctions that are located in the
intercalated disc of the atrial myocyte, and finally collecting in the atrioventricular
node (AV node). The intercalated discs also contain desmosomes, which allow
for cell-to-cell adhesion of adjacent cardiomyocytes. The AV node depolarizes in
a likewise fashion as the SA node (only if the SA node is not working), with
gradual depolarization through the If current generating an AP as previously
stated. All cells capable of generating an AP will depolarize and repolarize in a
similar manner. Atrial and ventricular cardiomyocytes receive the AP from the
conducting pathways. Due to the ventricles being separated from the atria by the
fibrous skeleton, modified cardiocytes are needed; atrioventricular node (AV
node), atrioventricular bundle (Bundle of His) and Purkinje fibers.
The cardiomyocytes begin to depolarize by AP’s from system conduction and
other heart muscle cells, until threshold is met at approximately -70 mV with
activated voltage-gated Na+ channels (Nav) initiating rapid depolarization (Phase
0). During phase 0, the myocytes will rapidly depolarize toward the Nernst
potential for Na+, about +60 mV, but will never fully reach it (1,4). These
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activated Nav will undergo a second transition to an inactivated state and will not
have the ability to reopen until transitioning back to a closed state. This is known
as the absolute refractory period (ARP), as a subsequent AP cannot fire during
this time because there are insufficient Nav in the closed state and available to
re-open (1). Phase 1 is initiated by the inactivation of the Nav and the opening of
the transient Kv4.2/4.3. During phase 2, Ca2+ rapidly enters the cardiomyocyte
from the extracellular fluid via L-type voltage-gated Ca2+ channels (Cav); the
subsequent influx of Ca2+ will lead to activation of ryanodine receptors (RyR)
located on the sarcoplasmic reticulum (SR) (1,4,5), through the process known
as calcium induced – calcium release which plays a vital role in excitationcontraction coupling in cardiac muscle (5). Calcium ions from the SR are then
released through activated RyR and bind to troponin, initiating the rippling
cascade of myocardial contraction (1,4,5). As phase 3 commences, the L-type
Cav begin to inactivate, and the delayed rectifier Kv (1.5) are activating and
thereby continue to allow potassium to flow freely returning the membrane
toward the Nernst potential for potassium (6-8). Phase 4, the final phase, the
membrane has returned to resting and is ready for another AP (6,7). These five
phases are understood as the normal electrical signaling of human heart muscle.
Here, we studied mouse ventricular voltage-gated ion channels (VGIC); as seen
in figure 2, Nav and Cav isoforms are very similar between human and mouse
cardiomyocytes; Kv particularly delayed rectifier Kv are quite different, explaining,
in part, the distinct AP waveforms of human versus mouse cardiomyocytes.
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Figure 2. Action potentials with underlying ion channels in the myocardium of mouse and
human ventricles. Image was taken (with permission) from Nerbonne (9).

This is, Nav 1.5 in humans and mice is responsible for the depolarization
phase. Cav1.2 is seen in both models. Kv 4.2 is looked at as being a transient Kv
and comparable to Kv 4.3 in the human model. Finally, Kv 1.5 and 2.1 are the
slower, delayed-rectifier, repolarizing channels in the mouse that allow the
myocyte to return to resting membrane potential. The most obvious difference in
the two models of mouse versus human are the types of Kv responsible for the
repolarization phase.
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B. Cardiac Dysfunction
Cardiomyopathies are divided into subtypes based on both morphological
and functional phenotypes and are some of the most common precursors to HF,
that lead to morbidity and mortality (24-27). Dilated cardiomyopathy (DCM) can
be characterized
by a thinning of
the left
ventricular (LV)
wall thickness
and dilation of
chambers – both
common after
new onset of

Figure 3: Known cardiomyopathies classification; ARVC,
arrhythmogenic right ventricular cardiomyopathy; DCM, dilated
cardiomyopathy; HCM, hypertrophic cardiomyopathy; RCM, restrictive
cardiomyopathy. Figure was adapted (with permission) from Elliot et. al
(8).

DCM (25,26,2830). On average, there are 600,000 new diagnoses of heart failure per year in
the United States with life expectancy after diagnosis approximately 5 years
(24,28). DCM takes the lives of 650,000 people annually, with the majority
having an idiopathic etiology (24-26,28,31). DCM plays a significant role in
sudden cardiac deaths; further, DCM patients are the most likely to receive heart
transplants in children and adults worldwide (25,26).
Heart failure (HF) is described as failure of the heart to pump blood
efficiently through the body, secondary to electrical and contractile dysfunction
(10). Patient’s will not only have circulatory issues, but they are more likely to
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develop arrhythmias (10,11). Heart failure has shown alterations in VGIC, gap
junctions, and structural changes (10). As described above, several VGIC
contribute to the normal generation of an AP and some channels are dependent
on each other and are responsible for the calcium induced – calcium release
mechanisms. Studies have shown a correlation between electrical and
mechanical dysfunction through channelopathies (10). Nav and KV mutations can
demonstrate a deficit in channel surface expression that may be linked to cardiac
diseases after removing the entire N-glycan (6,12). In our work, we have found
the modest changes in N- glycosylation that represents a more
pathophysiological scenario (we cannot live without N-glycosylation), in fact does
not change surface expression. This is unique, as other groups have removed
the entire N-glycan, which could potentially impact surface expression.
Cardiac dysfunction can affect the right or left ventricle; however,
congestive heart failure typically involves significant dysfunction of the left
ventricle (13). Though there is no cure for congestive heart failure, it can be
treated (14,15). Before science had evolved and treatment options became
available, patients with viral myocarditis, alcohol cardiomyopathy, and postpartum cardiomyopathy were the only ones who stood a chance to regain left
ventricular function (14). Today patients have the ability to be treated with bblockers (15-17), angiotensin receptor blockers (15,18), aldosterone receptor
blockers (15,19-21), angiotensin-converting enzyme (ACE) inhibitors (15,22), as
well as cardiac resychronisation therapy (15,23).
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C. Glycosylation and Cardiac Function
Normal cardiac function is needed to maintain a healthy life. In order to
maintain normal cardiac function, past studies have shown that
glycosyltransferases and glycosidases are required for normal homeostatic
physiology (33). Several glycan types can be linked to proteins, but the most
abundant are the oligosaccharides (N-linked glycans) (34-36). Oligosaccharides
can be added en bloc to the Asparagine residue that initiates the consensus Nglycosylation site of Asparagine-X-Serine/Theronine. Sugar residues are then
added to and removed from the N-glycan structure co-translationally in the lumen
of the rough endoplasmic reticulum (RER), and then possibly follow a designated
default pathway to several locations such as the plasma membrane,
peroxisomes, extracellular space, or other organelles (34). Initially, the
oligosaccharides are attached to dolichol (lipid) and then transferred to
asparagine (N) during translocation. N-glycans will reach the Golgi complex,
which is a common place for post-translational modification and packaging. Also,
the high-mannose glycans will become complexed/hybrid glycoproteins as they
make their way through the Golgi (37). This formation of oligosaccharides is a
critical cellular process that is necessary for sustainable cardiac function and
requires the activity of many glycogenes (32,38). The hybrid/complex N-glycans
are often directed to the sarcolemma with multiple proteins that range in function
from ion channels, receptors, and cell adhesion molecules (30,38). The
oligosaccharide chains are sensitive to enzymes that function to cleave complete
carbohydrate chains or single monosaccharides (34). Previous studies from the
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Bennett lab and others have shown glycogene expression that results in
abnormal glycosylation in cardiomyocytes of both atria and ventricles correlate
with arrhythmias, DCM and HF (24,32,38, 39-42). Furthermore, models with
DCM and HF have shown to be related to the abnormal glycosylation of voltage
gated ion channels (VGIC), particularly Nav and Cav (43,44). At the molecular
and cellular level, it has yet to be identified if the changes in cardiomyocyte
glycosylation is pathogenic or a consequence of DCM (38,44,45).

D. Role of Hybrid and Complex N-glycosylation in cardiac function
The glycosyltransferase, N-acetylglucosaminyltransferase 1 (GlcNAcT1),
is the gene product of mannosyl (a-1,3-)-glycoprotein b-1,2-Nacetylglucosaminyltransferase
(Mgat1) is responsible and
necessary for formation of the
complex/hybrid N-glycans in
the medial cisternae of the
Golgi apparatus.
Figure 4. Schematic of control vs Mgat1KO in mouse
ventricular cardiomyocytes. Figure was taken (with
permission) from Ednie et. Al (38).

Glycosylation occurs in the
cis Golgi network (CGN)

where the first N-acetylglucosamine (GlcNAc) residue is attached to a mannose
residue of the N-glycan structure (46). Proteins that reach GlcNAcT1 are
correctly folded; therefore, an unfolded protein response is unlikely exacerbated
by the deletion of Mgat1 (38,47,48). Studies have shown there are rare
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occasions that Mgat1 is reduced. Focusing on Mgat1 after being identified as a
critical gene in human idiopathic DCM (38,49), could show the role that
complex/hybrid N-glycosylation plays in cardiac function and heart diseases.
The Bennett lab has shown that modest changes in cardiac Nglycosylation directly modulate VGIC gating through electrostatic mechanisms,
but with no effect on channel surface expression; the sialylation-dependent
changes in VGIC gating are sufficient to increase susceptibility to cardiac
arrhythmias (50-53). Terminal sialic acid residues are negatively charged at
physiologic pH, and thereby contribute to the membrane potential sensed by the
voltage sensors of the VGIC such that channels gate at less depolarized
potentials in the presence of functional sialic acids. As glycosylation (sialylation)
is reduced, so is the negative external surface potential, and thereby VGIC gate
only following greater depolarizations. Recently, the Bennett lab showed that
these same reductions in sialylation are sufficient to also cause stressed-induced
heart failure suggesting a glycosylation-dependent link between excitability and
contraction in the heart (54). For this study we used our DCM mouse model
(Mgat1KO), to show the impact in VGIC dysfunctions after the deletion of protein
complexed/hybrid N-glycans.
Recently, and prior to my arrival to the lab, the Bennett lab successfully
established this unique mouse model with DCM secondary to pathologic
deletions of hybrid/complex N-glycosylation by developing a model where an
isolated glycosyltransferase gene, Mgat1, was knocked out in cardiomyocytes
only (55). Normal cardiac function is dependent on Mgat1 expression and has
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been seen to be down regulated in humans with end stage idiopathic DCM
(38,49, 55-58). GlcNAcT1, the Mgat1 gene product, is responsible and
necessary for the formation hybrid/complex N-glycans via the CGN, attaching the
first GlcNAc residue to a mannose residue (59). Therefore, GlcNAcT1 will only
act on proteins that have made it beyond the protein folding checkpoint in the ER
pathway (60). The Bennett lab showed that hybrid/complex N-glycans are
reduced in the cardiomyocyte membrane proteins of the Mgat1KO and develop
DCM that leads to an early death (55). Further, the Mgat1KO model confirmed
effects on myocyte e-c coupling and contraction, consistent with a direct effect on
Cava2d1 N-glycosylation that thereby impacts Cav gating.
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II.

Materials and Methods

Experimental animals
Experimental protocols were approved by the Institutional Animal Use and
Care Committee at Wright State University. The animals were handled following
the outline set by the NIH’s Guide for the Care and Use of Laboratory Animals.

Creation of Mgat1KO model
Creation and initial characterization of the cardiomyocyte-specific
Mgat1KO model was described in a recent publication from the Bennett lab (38),
in which the breeding, genotyping and selection of wild type and experimental
animals was described (38).

Western Blot and Immunodetection
To obtain whole protein lysates, hearts were homogenized using 1.5 mL
bead tubes that contained the following buffer (mM/L) Bis-Tris 20; pH7.2, EGTA
10, NaF 50, NaCl 100, Na+ pyrophosphate 25, MgSO4 3. We also added 0.02%
Na+ azide to act as a preservative, 1x Roche Complete Mini protease inhibitor
tablet, and 10 µM Calpain inhibitors I and II (APExBio). After the hearts were
homogenized, the lysates were brought to 1% glyco-diosgenin (Anatrace) from a
10% stock in lysis buffer. Protein solubilization took place at 1 hour with gentle
end-over-end mixing at 4° C and then centrifuged. SDS-PAGE and western
blotting conducting by using a Bis-Tris based buffer system as previously
described (38,50,51). Antibodies specifically for Kv2.1, Kv4.2 and Nav were used
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as previously described (50,51,53). Antibodies for Kv1.5 and MiRP1 were from
Alamone and the antibody for anti-KChiP2 came from Neuromab. The total
protein staining was carried out by adding 2,2,2-trichloroethanol to the running
gels as done in previous experiments (38) and all Western blots were analyzed
using Image Lab, software from Bio-Rad.

Data analysis and statistics
Excel (Microsoft) and Image Lab (Bio-Rad) software programs were used
to analyze the raw data collected. SigmaPlot (Systat Software) provided the
capability of statistical analyses and graphs and figures were made with Prism
(GraphPad). For statistical analysis, Student’s t-test was used as appropriate. P
values were calculated and were found to be statistically significant when p<
0.05. Data on graphs are presented as the mean ± SEM. Percent changes were
figured in as the absolute value of differences between Mgat1KO and control,
and compared to the control values. N was used to represent the sample size of
animal numbers.
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III.

Results

A manuscript by A.R. Ednie, A.R. Parrish, M.J. Sonner and E.S. Bennett
entitled, “Reduced Hybrid/Complex N-glycosylation Disrupts Cardiac Electrical
Signaling and Calcium Handling in a Model of Dilated Cardiomyopathy“, was
recently accepted for publication and can be found at the following URL:
https://doi.org/10.1016/j.yjmcc.2019.05.001. In this report, the lab investigated
whether there is a direct glycosylation-dependent functional linkage between
cardiac and cardiomyocyte electrical and contractile functions using our
Mgat1KO DCM mouse model. We concluded that the Mgat1KO ventricular
cardiomyocytes presented with a significant decrease in Kv expression leading to
APs of greater duration. The reduction in Ik (due to reduced Kv activity)
worsened with disease (DCM) progression, likely due to indirect effects of Mgat1
deletion. Furthermore, the lab was successful in showing that Nav gating is
depolarized in the Mgat1KO model, with Nav expression and conductance
unaffected, supporting that there is a direct electrostatic effect of Mgat1 deletion
on the Nav that contains fewer hybrid/complex N-glycans. Hence, the report in
FASEB J. by Ednie et al (38), together with the recent paper on which I am a coauthor (71), showed a drastic change in VGIC (Cav and Nav) gating that was
directly related to Mgat1 deletion, and consistent with an electrostatic
mechanism. Further, indirect effects on Mgat1 deletion resulted in reduced K+
current and Kv expression that were secondary to direct effects on VGIC gating
and worsened with disease progression.

14

My contribution to this work focused primarily on experiments designed to
determine the relative expression levels of the three major cardiac Kv isoforms,
and whether they were consistent with the observed significant, apparent
disease-related decrease in Mgat1KO Kv currents (IK) that occur during the
ventricular AP of the Mgat1KO. Further, I investigated whether the Nav
expression levels remained constant in control and Mgat1KO myocytes.
The three major Kv isoforms that are collectively responsible for ventricle
repolarization, Kv4.2 (Ito), Kv1.5 (IK,Slow1), and Kv2.1 (IK,Slow2), were targets of
interest for the reasons described above. Briefly, Dr. Andrew Ednie in the lab
showed that IK is reduced in 8-20 week old Mgat1KO ventricular myocytes
compared to control IK levels, but only modestly reduced in 4 week old ventricular
myocytes; together these data suggest that the reduction in IK may, at least in
part, be the result of ion channel remodeling that worsens with disease
progression. Thus, to determine whether Kv expression is reduced consistent
with the disease-related reductions in IK observed, total protein lysates were
collected from 16-20 week old Mgat1KO and control hearts, separated by SDSPAGE, Western blotted and finally probed with specific antibodies for the three Kv
isoforms. Kv1.5 and Kv4.2 expression levels were significantly lower in the
Mgat1KO hearts, compared to the controls (Fig. 5A and 5B, composite data in
Fig. 6). However, surprisingly Kv 2.1 (Fig 5C, 6) expression was higher in the
Mgat1KO hearts, which was not expected. Thus, Martha Sonner in the lab
questioned whether the reduction of Kv2.1 current could be due to reduced
surface expression. Specifically, Martha tagged surface proteins of
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cardiomyocytes with an amine-reactive biotin molecule. Using neutravidin
coated beads, allowed for the beads to adhere to the biotinylated surface
proteins. Kv2.1 surface protein expression was not seen to be affected in the
cardiomyocytes of the Mgat1KO (but was not increased in the Mgat1KO as
suggested by the whole cell lysate experiments, see Figs. 5C and 6). Analyzing
other channels in the Mgat1KO, surface expression of Kv1.5, Kv4.2 and the K+
channel interacting protein 2 (KChiP2), which regulates Kv4.2 expression (61)
were all significantly lower. However, the Kv auxiliary protein MiRP1 (KCNE2)
was significantly higher in the Mgat1KO (Fig 7; N=4; p≤0.04).
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Figure 5. Kv but not Nav expression is redued in the Mgat1KO ventricle; Nav is reduced in
molecular weight of Mgat1KO compared to controls. Top Panels: Immunoblots of whole
protein lysates that are probed with anti-VGIC antibodies. Bottom Panels: Gels corresponding
to the blot in the top panel stained for total protein. A) Nav. Nav expression is similar in the
ventricles of controls and Mgat1KO; however, there is a slight in molecular weight
(approximately 5 kD) in the Mgat1KO (N=3). (B) Kv1.5. (C) Kv4.2. (D) Kv2.1. The data suggest
that there is a reduction in expression of Kv1.5 and Kv4.2 and an increase in Kv2.1 expression
in the ventricles of Mgat1KO. Figure was adapted from Ednie, Parrish, Sonner, and Bennett,
2019.

Figure 6. Composite
data showing the relative
whole cell protein levels
of the three Kv isoforms
and Nav from Mgat1KO
(red) versus control
(black) lysates. Figure is
adapted from Ednie,
Parrish, Sonner, and
Bennett, 2019
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Figure 7. Work was completed by Martha Sonner, where surface proteins of cardiomyocytes
were tagged with an amine-reactive biotin molecule. The biotinylated proteins were collected,
Western blotted and probed with the appropriate antibodies. The surface protein/antibodies
were normalized to total protein, as described in the Methods. The bottom panel shows that
there is a reduction in surface expression of Kv4.2, Kv1.5 and KChiP2, in the cardiomyocytes
of Mgat1KO. However, the surface expression for MiRP1 was higher in the Mgat1KO
cardiomyocytes in comparison to the control (N=4; p≤0.04). There was no statistical
significant differences in the surface expression in Kv2.1 in Mgat1KO versus control, when
comparing the two groups. Figure is taken from Ednie, Parrish, Sonner, and Bennett, 2019.
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Nav expression nor INa in Mgat1KO and control were different, but unlike
Kv, Nav is apparently a direct GlcNAcT1 target. There was no significant
difference in the expression comparing Mgat1KO and control ventricles as
indicated in the Nav Western blot (Figs. 5A, 6). There was a slight reduction in
predicted molecular weight of the Mgat1KO Nav (Fig. 5A), which suggests that
Mgat1KO contains Nav channels that are less N-glycosylationed and are thus a
likely direct GlcNAcT1 target. To determine if Kv1.5 (Kv4.2 and Kv2.1 are not Nglycosylated, and thus cannot be GlcNAcT1 targets) are also potential direct
targets of GlcNAcT1, immunoblot gel shift analyses were performed using whole
protein lysates from the Mgat1KO and control ventricles (Fig. 8).

Figure 8. (A) Mgat1KO Cava2d1 after being treated with Endo-H shows sensitivity meaning
that it is a target for GlcNAcT1. (B) and (C) are both probed with antibody specific for Kv1.5
after being treated with Endo-H and PNGase-F respectively. Both blots showed no sensitivity
to either enzyme treatment in the control or in the Mgat1KO lysates, as there was not a
noticeable shift in molecular weight, suggesting Kv1.5 is not a target for GlcNAcT1.

Endoglycosidase H (Endo-H) and Peptide: N-glycosidase F (PNGase F) are
commonly used enzymes that will cleave off high mannose and full Nglycoproteins respectively. Previously, Dr. Ednie showed, using this pair of
enzymes, that the Cava2d1 is a target for GlcNAcT (38), which we further
confirmed here in Figs. 8 and 10. Kv4.2 and Kv2.1 do not contain any putatively
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extracellular consensus N-glycosylation sites (NXS/T), and therefore neither Kv
isoform can be GlcNAcT1 targets. On the other hand, Kv1.5 does contain one
potential external N-glycosylation site. However, as can be seen in Figs. 8 and
9, our data suggest that Kv1.5 is not a GlcNAcT1 target.

Figure 9.
Top panel. Immunoblot, probed with an antibody specific for Kv1.5 showed no enzyme
sensitivity. Whole protein lysates of ventricular cardiomyocytes were treated with Endo-H and
compared to untreated lysates.
Bottom panel. Immunoblot, probed with a second antibody for Kv1.5 from Santa Cruz, to
confirm it is not a target for GlcNAcT1. Whole protein lysates of ventricular cardiomyocytes
were treated with Endo-H and compared to untreated lysates.
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With that stated, the predicted increased electrophoretic mobility represented by
a decreased molecular weight (MW) in the Mgat1KO Kv1.5 should it be a
GlcNAcT1 target, would be quite small (hundreds of daltons), and thus, we will
need to perform more sensitive assays such as HILIC analysis similar to that
does by us previously (38) to determine more rigorously whether Kv1.5 is a direct
GlcNAcT1 target. Regardless, the further reduction with disease progression, in
IK,slow1, which is produced by Kv1.5 activity, along with the disease-related
reductions in Kv4.2 (Ito) and Kv2.1 (IK,slow2) activities, strongly suggests that there
is at least some disease-related indirect effects of Mgat1 deletion on Kv activities,
and as a result, disease-related remodeling and reduction in IK.

Figure 10. Immunoblot, probed with an antibody specific for Cava2d1 showed
enzyme sensitivity, confirming that Cava2d1 is a target for GlcNAcT1. Whole protein
lysates of ventricular myocytes were treated with Endo-H compared to untreated
lysates.
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IV.

Discussion

In our recent publication by Ednie, Parrish, Sonner, and Bennett (71),
entitled, “Reduced Hybrid/Complex N-glycosylation Disrupts Cardiac Electrical
Signaling and Calcium Handling in a Model of Dilated Cardiomyopathy“, we
showed that Nav gating was directly altered by Mgat1 deletion through
mechanisms consistent with an electrostatic mechanism. Further, indirect effects
of Mgat1 deletion resulted in reduced K+ current and Kv expression that were at
least secondary to direct effects on Nav and Cav gating and worsened with disease
progression. Together, these direct and indirect effects of Mgat1 deletion resulted
in extended cardiomyocyte APs, pacing-induced early re-activation events, and
altered Ca2+ handling as well as aberrant conduction across the heart.
Here we found that (Fig. 5A), when comparing to previous studies done in
the lab, that Mgat1 deletion in cardiomyocytes suggest there is no further effect
on the function of Nav other than a reduced negative surface potential caused by
reductions in Nav sialic acids. There was no change in Nav expression, but there
was a reduction in channel molecular weight, suggesting that Nav, like Cava2d1, is
a GlcNAcT1 target. These effects support the observed changes in AP
properties of Mgat1KO ventricular myocytes.
Relative to Kv expression, we found that Kv4.2 and Kv1.5 are significantly
reduced in the 16-20 week old Mgat1KO compared to the age-matched control.
These data are consistent with the significantly reduced Ito and IK,Slow1 that
worsens with age as shown by Andrew Ednie in our recent publication (71).
Further, we showed that surface expression of these two Kv isoforms are
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significantly lower in the Mgat1KO ventricular myocyte compared to controls (Fig.
8).
The increased expression of Kv2.1 (Fig. 5C), and even the lack of the
reduction in Kv2.1 surface expression was surprising; however, the data are
consistent with a study analyzing the impact of repolarization in a transaortic
constriction mouse model with cardiac hypertrophy (64). McCrossan et. al,
showed that MiRP1, an auxiliary subunit, can reduce expression of Kv2.1 activity
and slow down inactivation, similar to that shown here in our recent publication
(72). We showed, in figure 7, that MiRP1 surface expression is significantly
higher in the cardiomyocytes of Mgat1KO. Thus, it is a possibility that the
deletion of Mgat1 regulates the effects of Mgat1 deletion on Kv2.1, after an
increase in surface expression of MiRP1. More testing is required to solidify this
possible mechanism.
Kv1.5 has been seen to be a direct target of cardiac remodeling (64,65)
and is downregulated in models with DCM (66). Therefore, there are two main
ideas: Kv1.5 is an early target of cardiac remodeling and/or a direct GlcNAcT1
target. Our results suggest that Kv1.5 is not a target of GlcNAcT1 (Fig 9). In
addition, other labs have shown that there were effects of reduced glycosylation
on surface expression of the Kv isoforms, but in these studies by others,
glycosylation was completely removed either through mutation of the Nglycosylation site or using chemicals to remove or inhibit the complete N-glycan
(12, 68). This is servere and not commonly seen in pathological glycosylation
reductions. Our lab’s DCM mouse model prevents only hybrid/complex N-
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glycosylation and in cardiomyocytes only, thus not affecting the core N-glycan
structure (Fig 4). This model is more comparable to glycosylation-deficient
diseases known as congenital disorders of glycosylation. As mentioned
previously, GlcNAcT1 functions in the Golgi apparatus, specifically medial portion
initiating hybrid/complex N-glycosylation. Prior to this along the N-glycosylation
pathway, there is the protein-folding checkpoint of the ER pathway, verifying that
proteins are correctly folded (47). GlcNAcT1 acts after the ER protein checkpoint,
likely ensuring the proper folding of proteins in the Mgat1KO myocyte. Finally,
Dr. Ednie, in our recent publication, showed that IK is further reduced as DCM
progresses in the Mgat1KO (71). Together, these data strongly suggest that
reduced Kv expression and activity, including for Kv1.5, is an indirect effect of
Mgat1 deletion that is exacerbated as heart disease progresses.

Correlation of VGIC activity to heart disease
Currently, there are numerous Nav mutations correlatedto cardiac arrhythmic
DCM (62,63). Studies comparing the progression of disease and the Nav
dysfunction is obscure (63), but it is known that of the seventeen best understood
DCM-related Nav mutants, five have mutations result in a rightward-shift in
steady-state activation, inactivation or both, similar to that seen in our recent
paper, for Mgat1KO Nav gating (62). Thus, ongoing studies in the lab will
question whether disease progression can be slowed in the Mgat1KO heart via
targeting Nav activity. These research studies may lead to the development of
new therapeutic techniques in treating patients who present with congenital
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disorders of glycosylation or patient’s with Nav mutations correlated to DCM.
There is an extreme importance of Kv1.5, as it is understood to have a significant
role in the linage to human atrial fibrillation (68). As the studies pertaining to
aberrant glycosylation continue, utilizing the Mgat1KO DCM model will be a very
useful tool.
As mentioned earlier, the direct, right-ward shift in Nav gating causes the
slower inactivation of the channels, which then increases the influx of Na+ during
the prolonged AP. This dramatic influx of Na+ has been linked to the disruption
of Ca2+ homeostasis and leading to arrhythmias (61,70). The three Kv isoforms
are very likely indirectly affected through prolonged cardiac disease.

Future studies
As our lab continues to study hybrid/complex N-glycans, other projects will aid
in the bigger picture of our project and allow for a deeper understanding to DCM.
It would be beneficial in determining the actual distribution of the effects of
deletion of the enzyme, GlcNAcT1. To determine this, one could use the
biotinylated Galanthus Niavalis Lectin (GNL), a carbohydrate-binding protein that
binds specifically to mannose-specific lectins (the dominant N-glycan structure in
Mgat1KO myocytes). However, unlike other mannose-specific lectins, GNL does
not require Ca2+ or Mn2+. The questions we ask pertaining to this are, will we
even see the distribution? or Can we determine the percent of the
cardiomyocytes that are complete or partial KO? It is also of interest that we try
to find the time window of when fibrotic tissue presents itself on the gross level

25

on mice with Mgat1KO. Paraffin fixation with trichrome blue stain would be an
option as well as cryofixation paired with using a cryostat. Finally, measuring the
functionality of gap junctions that are located in the intercalated disc of cardiac
tissue.

V.

Conclusion

The glycosylation of proteins is ubiquitous to molecular and cellular processes
and can even be thought to have an evolutionary purpose. Understanding the
role of glycosylation gives scientist a greater knowledge of how this affects
human health and relates to the cause of disease. However, the research on
aberrant N-glycosylation is elusive, and there are multiple questions on cardiac
dysfunction that are not understood. What is known is that the defects in
glycosylation and glycogene expression leads to cardiac diseases such as DCM,
which is typically accompanied by arrhythmias. Unfortunately, the functional
linkage between altered glycosylation and disease progression is not fully
understood. Our lab, through efforts made in this project and in previous studies,
showed that reduced hybrid/complex N-glycosylation directly and indirectly
modulates cardiomyocyte and cardiac electrical signaling. Our recent paper (71)
provides a possible explanation that links these direct and indirect mechanisms
to the abnormal contractions leading to DCM in the Mgat1KO and the onset of
cardiac disease (38). Utilization of this mouse model will allow one to continue
uncovering the linkage between cardiac diseases and aberrant N-glycosylation.
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